
T2 Biosystems TTOO
Quarterly report 2024-Q3
added 05-16-2026
T2 Biosystems Book Value 2011-2026 | TTOO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28 M | -39.7 M | -12.9 M | 8.73 M | -34 M | 11.4 M | 1.34 M | 39.3 M | 46.8 M | 53 M | -89.5 M | -62.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53 M | -89.5 M | -8.85 M |
Quarterly Book Value T2 Biosystems
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.7 M | -5.9 M | -37.8 M | -28 M | -19.2 M | -36.4 M | -49.9 M | -39.7 M | 44 M | 39.6 M | 49 M | 60.5 M | 70 M | 78.9 M | 70.1 M | 79.1 M | 77.6 M | 53.7 M | 51.4 M | 28.5 M | 34.3 M | 45.2 M | 55.6 M | 64.3 M | 75.9 M | 84.2 M | 42.1 M | 54.9 M | 69.7 M | 63.8 M | 75.7 M | 89.6 M | 92 M | 65.9 M | 74.9 M | 86.8 M | 53.1 M | 63.7 M | 72.8 M | 79.1 M | 78.9 M | 20.1 M | 79.1 M | 31.9 M | 31.9 M | 31.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 92 M | -49.9 M | 45.5 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
Celcuity
CELC
|
101 M | $ 88.28 | -4.53 % | $ 4.13 B | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 5.63 | -2.26 % | $ 7.49 M | ||
|
Castle Biosciences
CSTL
|
471 M | $ 21.01 | -2.73 % | $ 609 M | ||
|
Fulgent Genetics
FLGT
|
1.11 B | $ 19.15 | -1.79 % | $ 589 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-56 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
-99.3 M | $ 125.61 | -5.6 % | $ 15.7 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.67 | -6.7 % | $ 7.39 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Illumina
ILMN
|
6.64 B | $ 162.32 | -3.42 % | $ 25.2 B | ||
|
CareDx, Inc
CDNA
|
303 M | $ 22.25 | -3.76 % | $ 1.19 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
9.19 B | $ 149.45 | -2.19 % | $ 11.7 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 100.98 | -1.79 % | $ 6.82 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
1.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
837 M | $ 10.9 | -3.63 % | $ 1.4 B | ||
|
Natera
NTRA
|
1.71 B | $ 215.31 | -3.06 % | $ 29.4 B | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 181.34 | -2.4 % | $ 8.99 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.45 | -11.04 % | $ 435 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 454.25 | -0.97 % | $ 13.1 B | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 154.33 | -2.22 % | $ 23.8 B | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.57 | -2.56 % | $ 423 M | ||
|
National Research Corporation
NRC
|
14 M | $ 19.14 | -3.09 % | $ 428 M | ||
|
Personalis
PSNL
|
261 M | $ 10.75 | -11.16 % | $ 959 M | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 26.11 | 0.46 % | $ 24.8 B | ||
|
Senseonics Holdings
SENS
|
61 M | $ 6.67 | -4.85 % | $ 278 M | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
450 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.12 | -1.17 % | $ 4.87 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 265.15 | 1.6 % | $ 22.1 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 69.22 | -6.37 % | $ 4.14 B | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 472.8 | -1.91 % | $ 178 B | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.67 | -2.43 % | $ 241 M | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
2.56 B | $ 365.36 | -2.95 % | $ 21.8 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 8.9 | -2.41 % | $ 1.93 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 200.29 | 2.13 % | $ 22.2 B |